These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 10661908)

  • 1. Hypothesis: thalidomide embryopathy-proposed mechanism of action.
    Stephens TD; Fillmore BJ
    Teratology; 2000 Mar; 61(3):189-95. PubMed ID: 10661908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action in thalidomide teratogenesis.
    Stephens TD; Bunde CJ; Fillmore BJ
    Biochem Pharmacol; 2000 Jun; 59(12):1489-99. PubMed ID: 10799645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Misregulation of gene expression in the redox-sensitive NF-kappab-dependent limb outgrowth pathway by thalidomide.
    Hansen JM; Gong SG; Philbert M; Harris C
    Dev Dyn; 2002 Oct; 225(2):186-94. PubMed ID: 12242718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fetal malformations and early embryonic gene expression response in cynomolgus monkeys maternally exposed to thalidomide.
    Ema M; Ise R; Kato H; Oneda S; Hirose A; Hirata-Koizumi M; Singh AV; Knudsen TB; Ihara T
    Reprod Toxicol; 2010 Jan; 29(1):49-56. PubMed ID: 19751816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PBX, MEIS, and IGF-I are potential mediators of retinoic acid-induced proximodistal limb reduction defects.
    Qin P; Cimildoro R; Kochhar DM; Soprano KJ; Soprano DR
    Teratology; 2002 Nov; 66(5):224-34. PubMed ID: 12397630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor-beta3 promotes mesenchymal cell proliferation and angiogenesis mediated by the enhancement of cyclin D1, Flk-1, and CD31 gene expression during CL/Fr mouse lip fusion.
    Muraoka N; Shum L; Fukumoto S; Nomura T; Ohishi M; Nonaka K
    Birth Defects Res A Clin Mol Teratol; 2005 Dec; 73(12):956-65. PubMed ID: 16323168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-beta3 inhibits chondrogenesis of cultured chick leg bud mesenchymal cells via downregulation of connexin 43 and integrin beta4.
    Jin EJ; Lee SY; Jung JC; Bang OS; Kang SS
    J Cell Physiol; 2008 Feb; 214(2):345-53. PubMed ID: 17620312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of programmed cell death and gene expression by 5-bromodeoxyuridine during limb development in mice.
    Nakamura N; Fujioka M; Mori C
    Toxicol Appl Pharmacol; 2000 Sep; 167(2):100-6. PubMed ID: 10964760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Abnormalities of internal organs in thalidomide embryopathy. A contribution to the determination of the sensitivity phase in thalidomide administration during early pregnancy].
    Kreipe U
    Arch Kinderheilkd; 1967 Aug; 176(1):33-61. PubMed ID: 5595238
    [No Abstract]   [Full Text] [Related]  

  • 10. Retinoids as teratogens.
    Soprano DR; Soprano KJ
    Annu Rev Nutr; 1995; 15():111-32. PubMed ID: 8527214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide on the comeback trail.
    Hales BF
    Nat Med; 1999 May; 5(5):489-90. PubMed ID: 10229222
    [No Abstract]   [Full Text] [Related]  

  • 12. Of meis and men: lessons from a microarray study of teratogen action.
    Docterman KE; Smith SM
    Teratology; 2002 Nov; 66(5):217-23. PubMed ID: 12397629
    [No Abstract]   [Full Text] [Related]  

  • 13. Evidence for teratogenicity of thalidomide using congenic and recombinant inbred rat strains.
    Bílá V; Kren V
    Folia Biol (Praha); 1994; 40(4):161-71. PubMed ID: 7851614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesonephros has a role in limb development and is related to thalidomide embryopathy.
    Smith DM; Torres RD; Stephens TD
    Teratology; 1996 Sep; 54(3):126-34. PubMed ID: 8987155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the developmental toxicity of lenalidomide in rabbits.
    Christian MS; Laskin OL; Sharper V; Hoberman A; Stirling DI; Latriano L
    Birth Defects Res B Dev Reprod Toxicol; 2007 Jun; 80(3):188-207. PubMed ID: 17570132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teratogen update: clinical aspects of thalidomide embryopathy--a continuing preoccupation.
    Newman CG
    Teratology; 1985 Aug; 32(1):133-44. PubMed ID: 4035587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comments on "Proposed Mechanisms of Action in Thalidomide Embryopathy".
    Koch HP
    Teratology; 1990 Feb; 41(2):243-6. PubMed ID: 2321169
    [No Abstract]   [Full Text] [Related]  

  • 18. Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.
    Crofts F; Rohatagi S; Pino M; DeLise B; Zhang J; Nguyen M; Guittin P; Barbellion S; Brunel P; Hofmann T; Schmidt J; Wong M; Lockey P; Lerman S; Clark R
    Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):69-79. PubMed ID: 15098200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A developmental model for thalidomide defects.
    Tabin CJ
    Nature; 1998 Nov; 396(6709):322-3. PubMed ID: 9845068
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanisms of teratogenesis.
    Saxén L
    J Embryol Exp Morphol; 1976 Aug; 36(1):1-12. PubMed ID: 789808
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.